CVAC 2.83 CureVac N.V.
| Range: | 2.215-6.3 | Vol Avg: | 576359 | Last Div: | 0 | Changes: | 0.04 |
| Beta: | 2.61 | Cap: | 0.65B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Aug 14 2020 | Empoloyees: | 999 | ||
| CUSIP: | N2451R105 | CIK: | 0001809122 | ISIN: | NL0015436031 | Country: | DE |
| CEO: | Dr. Alexander Zehnder M.B.A., M.D. | Website: | https://www.curevac.com | ||||
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow